HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

carboxypeptidase M

from human placental microvilli; MW 62kDa; cleaves Arg or Lys from the COOH terminus of synthetic peptides as well as several biologically active substrates; membrane-bound; structurally, catalytically & immunologically distinct from carboxypeptidase A,B,N & H
Also Known As:
CPM protein, human; Cpm protein, mouse; Cpm protein, rat; carboxypeptidase M, human; carboxypeptidase M, mouse; carboxypeptidase M, rat
Networked: 23 relevant articles (0 outcomes, 2 trials/studies)

Bio-Agent Context: Research Results

Experts

1. Denis, Catherine J: 3 articles (03/2013 - 01/2013)
2. Lambeir, Anne-Marie: 3 articles (03/2013 - 01/2013)
3. Couture, Réjean: 2 articles (01/2017 - 01/2016)
4. Haddad, Youssef: 2 articles (01/2017 - 01/2016)
5. Scharfstein, Julio: 2 articles (01/2017 - 01/2011)
6. Hendriks, Dirk: 2 articles (03/2013 - 01/2013)
7. Dezso, Balazs: 2 articles (03/2012 - 04/2008)
8. Nemes, Zoltan: 2 articles (03/2012 - 04/2008)
9. Soos, Gyorgyike: 2 articles (03/2012 - 04/2008)
10. Tsakiris, Ioannis: 2 articles (03/2012 - 04/2008)

Related Diseases

1. Insulin Resistance
2. Lymphoma (Lymphomas)
3. Inflammation (Inflammations)
01/01/2011 - "Tightly regulated by angiotensin-converting enzyme, the intact kinins (BK(2)R agonists) may be processed by carboxypeptidase M/N, generating [des-Arg]-kinins, which activates BK(1)R, a subtype of GPCR that is upregulated by cardiovascular cells during inflammation. "
01/01/2017 - "As inflammation persists, a GPI-linked carboxypeptidase M removes the C-terminal arginine from the primary kinin, converting the B2R agonist into a high-affinity ligand for B1R, a GPCR subtype that is transcriptionally upregulated in injured/inflamed tissues. "
01/01/1992 - "A reduction of epithelial cell-bonded enzyme (carboxypeptidase M-type or kininase I), produces inflammations by the active intact kinins and the initiation of the alternative activating pathway of complement by active anaphilotoxins, which generate complement cleavage products, containing potential destructive mechanism."
08/01/2012 - "In vitro and in vivo experiments documented that platelet-derived growth factor receptor-β, carboxypeptidase M, carbonic anhydrase 12, receptor activity-modifying protein 1, and low-density lipoprotein receptor-related protein were the 5 specific surface markers regulating various SMPC functions, including migration, extracellular matrix formation, resistance to hypoxia, and anti-inflammation. "
01/01/2016 - "Whereas the treatment with 1400W had no impact on the elevated systolic blood pressure and leptin levels in glucose-fed rats, it significantly reversed or attenuated hyperglycaemia, hyperinsulinaemia, insulin resistance (HOMA index), body weight gain, peroxynitrite formation (nitrotyrosine expression) and the up-regulation of biomarkers of inflammation (B1 receptor, carboxypeptidase M, iNOS and IL-1β) in renal cortex and aorta and to some extent in the liver. "
4. Neoplasms (Cancer)
5. Granuloma

Related Drugs and Biologics

1. Enzymes
2. Heme Oxygenase-1
3. Dipeptidyl Peptidase 4 (Dipeptidyl Peptidase IV)
4. Cytoglobin
5. Proteins (Proteins, Gene)
6. Kinins
7. Biomarkers (Surrogate Marker)
8. Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)
9. ErbB Receptors (EGF Receptor)
10. Receptor Activity-Modifying Protein 1